Diabetes technology & therapeutics最新文献

{"title":"Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study.","authors":"Timothy S Bailey, David R Liljenquist, Douglas S Denham, Ronald L Brazg, Sorin Ioacara, James Masciotti, Samanwoy Ghosh-Dastidar, Katherine S Tweden, Francine R Kaufman","doi":"10.1089/dia.2024.0592","DOIUrl":"https://doi.org/10.1089/dia.2024.0592","url":null,"abstract":"<p><p>The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes. Accuracy and adverse events (AEs) were assessed during 14 in-clinic visits comparing CGM and Yellow Springs Instrument reference glucose measurements, including during hyperglycemia and hypoglycemia challenges. In total, 110 participants were implanted with the Eversense 365 CGM System. The overall mean absolute relative difference was 8.8% with primarily one calibration per week. The confirmed alert detection rate at 70 mg/dL was 96.6%, and at 180 mg/dL, it was 97.9%. Ninety percent of the sensors survived 365 days. Interoperable CGM special controls were met. No related serious AEs were reported. The Eversense 365 CGM was shown to be safe and accurate through 1 year with primarily one calibration per week.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Improvements in Glycemia and User-Reported Outcomes Associated with Open-Source Automated Insulin Delivery Systems in Adults with Type 1 Diabetes in the United Kingdom: A Real-World Observational Study.","authors":"Alexandros L Liarakos, Thomas S J Crabtree, Sufyan Hussain, Rachel Patel, Anastasios Gazis, Buddhike Mendis, Roselle Herring, Adele Kennedy, Neil Black, Robert E J Ryder, Emma G Wilmot","doi":"10.1089/dia.2024.0556","DOIUrl":"https://doi.org/10.1089/dia.2024.0556","url":null,"abstract":"<p><p><b><i>Objective:</i></b> To evaluate real-world outcomes in adults with type 1 diabetes initiating open-source automated insulin delivery systems (OS-AID). <b><i>Methods:</i></b> Adults with type 1 diabetes who commenced OS-AID, between May 2016 and April 2021, across 12 centers in the United Kingdom were included. Anonymized clinical data, collected during routine clinical care between December 2019 and November 2023, were submitted to a secure web-based tool within the National Health Service network. Outcomes included change in hemoglobin A1c (HbA1c), sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), user opinion of OS-AID, and event rates (hospital admissions, paramedic callouts, severe hypoglycemia, and adverse events) between baseline and follow-up. <b><i>Results:</i></b> In total, 81 OS-AID users were included (51.9% male; 90.1% White British; mean age 41.4 years; median diabetes duration 25 years [IQR 17-32]). Over a mean follow-up of 1.7 years, HbA1c reduced by 0.8% (9 mmol/mol) (7.3 ± 1.1% vs. 6.5 ± 0.7%; <i>P</i> < 0.001), and the percentage of individuals achieving HbA1c ≤ 7.0% (53 mmol/mol) increased from 48.6% to 75.7% (<i>P</i> < 0.001). Diabetes-related distress score reduced by 0.9 (95% confidence interval [CI] -0.3, -1.5; <i>P</i> = 0.006), and Gold score reduced by 0.7 (95% CI -0.1, -1.3; <i>P</i> = 0.022). The percentage of individuals with impaired hypoglycemia awareness (Gold score ≥4) reduced (27.8% at baseline vs. 8.3% at follow-up; <i>P</i> = 0.039). Of those asked, all participants stated that OS-AID had a positive impact on quality of life. The number of hospital admissions was low. <b><i>Conclusions:</i></b> The use of OS-AID is associated with long-term improvements in HbA1c, hypoglycemia awareness, and diabetes-related distress in type 1 diabetes. These benefits were achieved without increased rates of hospital admissions, diabetic ketoacidosis, or severe hypoglycemia.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ranting in 2025: It's Not the Same Rant.","authors":"Irl B Hirsch","doi":"10.1089/dia.2025.0005","DOIUrl":"https://doi.org/10.1089/dia.2025.0005","url":null,"abstract":"","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Admitted to Hospital: A Real-World Multicenter Observational Study.","authors":"Ray Wang, Mervyn Kyi, Brintha Krishnamoorthi, Jason Tjahyadi, Ailie Connell, Cherie Chiang, Debra Renouf, Rahul Barmanray, Spiros Fourlanos","doi":"10.1089/dia.2024.0604","DOIUrl":"https://doi.org/10.1089/dia.2024.0604","url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Continuous glucose monitoring (CGM) use in people with type 1 diabetes (T1D) is revolutionizing management. Use of CGM in hospital is poised to transform care, however routine use is not currently recommended due to lack of accuracy validation in acute care, including in people with T1D. We aimed to determine real-world CGM accuracy in hospitalized adults with T1D. <b><i>Materials and Methods:</i></b> In this multicenter retrospective observational study, we compared CGM interstitial fluid glucose with reference blood glucose (capillary/whole-blood point-of-care [POC], blood gas [GAS]) in adults with T1D requiring multiday admissions during 2020-2023 across three health services in Australia. Patients requiring dialysis or admitted under pediatric/obstetric/palliative care/psychiatry units were excluded. CGM accuracy was assessed by comparison with time-matched (±5 min) reference glucose measures, utilizing median absolute relative difference (ARD), mean ARD (MARD), and consensus error grid (CEG) analysis. <b><i>Results:</i></b> In total, 2,199 CGM-reference glucose pairs from 214 admissions (146 patients) were assessed. Overall, mean (SD) ARD was 12.8% (13.1) and median (IQR) ARD was 9.4% (3.7-17.7). MARD for CGM-POC pairs was 12.3%; MARD for CGM-GAS pairs was 14.3%. In CEG analysis, 99.3% of glucose pairs were within zones A/B. Accuracy was lower in critical care compared with noncritical care wards (MARD 16.1% vs. 12.0%, <i>P</i> < 0.001). <b><i>Conclusions:</i></b> In this real-world multicenter study, CGM glucose agreed well with reference blood glucose, suggesting modern CGM devices could be safely and effectively used in hospitalized adults with T1D. Further prospective studies of CGM accuracy with newer generation devices across different scenarios will further elucidate inpatient CGM accuracy and safety.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of the Dexcom G7 Continuous Glucose Monitoring Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA-2 Study).","authors":"Parizad Avari, Reshaba Pushparatnam, Lala Leelarathna, Tricia Tan, Andrew H Frankel, Nick Oliver, Monika Reddy","doi":"10.1089/dia.2024.0575","DOIUrl":"https://doi.org/10.1089/dia.2024.0575","url":null,"abstract":"<p><p>The accuracy of the latest generation Dexcom G7 sensors in individuals with diabetes undergoing hemodialysis has not previously been investigated. Participants with diabetes undergoing hemodialysis were recruited, with paired sensor glucose from Dexcom G7 recorded with plasma glucose analyzed in the laboratory, as well as the Freestyle Precision Pro glucometer and EKF Biosen C-Line analyzer. Ten adults (median age 64.0 [58.0-74.5] years) were recruited. Overall percentage (%) mean and median absolute relative differences were 10.4% and 8.5% for matched laboratory pairs, respectively (<i>n</i> = 720). Diabetes Technology Society error grid analysis showed 99.7%, 100%, and 99.9% of pairs within zones A and B for lab, glucometer, and EKF methods, respectively. This, the first Dexcom G7 accuracy study conducted in people on hemodialysis, demonstrates accuracy and safety when compared with lab reference readings. These data support the accessibility of continuous glucose monitoring (CGM) and hybrid closed-loop systems for people with diabetes on hemodialysis.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparison of Glucose and Additional Signals for Three Different Exercise Types in Adolescents with Type 1 Diabetes Using a Hybrid Closed-Loop System.","authors":"Rowen Seckold, Carmel E Smart, David N O'Neal, Michael C Riddell, Jordan Rafferty, Dale Morrison, Varuni Obeyesekere, Judy L Gooley, Barbora Paldus, Sarah R Valkenborghs, Sara Vogrin, Dessi P Zaharieva, Bruce R King","doi":"10.1089/dia.2024.0254","DOIUrl":"https://doi.org/10.1089/dia.2024.0254","url":null,"abstract":"<p><p><b><i>Objective:</i></b> To compare glycemic outcomes during and following moderate-intensity exercise (MIE), high-intensity interval exercise (HIE), and resistance exercise (RE) in adolescents with type 1 diabetes (T1D) using a hybrid closed-loop (HCL) insulin pump while measuring additional physiological signals associated with activity. <b><i>Methods:</i></b> Twenty-eight adolescents (average age 16.3 ± 2.1 years, 50% females, average duration of T1D 9.4 ± 4 years) using HCL (Medtronic MiniMed 670G) undertook 40 min of MIE, HIE, and RE. A temporary glucose target (8.3 mmol/L, 150 mg/dL) was set for 2 h prior and during exercise. Heart rate, accelerometer, venous glucose, lactate, ketones, and counter-regulatory hormones were measured for 280 min postexercise commencement. The primary outcome was glucose percentage time in range (TIR): 3.9-10 mmol/L (70-180 mg/dL) for 14 h from exercise onset. <b><i>Results:</i></b> Median (interquartile range) TIR for HIE was 88 (78, 96)%, MIE 79 (63, 88)%, and RE 86 (72, 95)% for 14 h from exercise onset. For MIE compared with HIE, TIR was lower (<i>P</i> = 0.012) and time above range (TAR) was greater (18 [2.4, 28] vs. 6.9 [0.0, 14]%, <i>P</i> = 0.041). Hypoglycemia occurred in 13 (46%), 11 (39%), and 14 (50%) of participants for HIE, MIE, and RE, respectively, the majority following the meal after exercise. There were higher levels of lactate (<i>P</i> = 0.001), growth hormone (<i>P</i> = 0.001), noradrenaline (<i>P</i> = 0.001), and heart rate (<i>P</i> = 0.01) during HIE and RE compared with MIE. <b><i>Conclusions</i></b>: HCL use in adolescents with T1D results in excellent TIR during different forms of exercise when a temporary target is set 2 h before. Extending the temporary target after exercise may also be needed to help minimize postexercise hypoglycemia.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Correction to:</i> Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (doi: 10.1089/dia.2023.0390).","authors":"","doi":"10.1089/dia.2023.0390.correx","DOIUrl":"https://doi.org/10.1089/dia.2023.0390.correx","url":null,"abstract":"","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications.","authors":"Boris P Kovatchev, Benjamin Lobo, Chiara Fabris, Mohammadreza Ganji, Anas El Fathi, Marc D Breton, Lauren Kanapka, Craig Kollman, Tadej Battelino, Roy W Beck","doi":"10.1089/dia.2024.0404","DOIUrl":"https://doi.org/10.1089/dia.2024.0404","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Using a multistep machine-learning procedure, add virtual continuous glucose monitoring (CGM) traces to the original sparse data of the landmark Diabetes Control and Complications Trial (DCCT). Assess the association of CGM metrics with the microvascular complications of type 1 diabetes observed during the DCCT and establish time-in-range (TIR) as a viable marker of glycemic control. <b><i>Research Design and Methods:</i></b> Utilizing the DCCT glycated hemoglobin data obtained every 1 or 3 months plus quarterly 7-point blood glucose (BG) profiles in a multistep procedure: (i) utilized archival BG traces to model interday BG variability and estimate glycated hemoglobin; (ii) trained across the DCCT BG profiles and associated each profile with an archival BG trace; and (iii) used previously identified CGM \"motifs\" to associate a CGM trace to a BG trace, for each DCCT participant. <b><i>Results:</i></b> TIR (70-180 mg/dL) computed from virtual CGM data over 14 days prior to each glycated hemoglobin measurement reproduced the observed glycemic control differences between the intensive and conventional DCCT groups, with TIR generally >60% and <40% in these groups, respectively. Similar to glycated hemoglobin, TIR was associated with the risk of development or progression of retinopathy, nephropathy, and neuropathy (all <i>P</i>-values <0.0001). Poisson regressions indicated that TIR predicted retinopathy and microalbuminuria similarly to the original glycated hemoglobin data. <b><i>Conclusions:</i></b> The landmark DCCT was revisited using contemporary data science methods, which allowed adding individual CGM traces to the original data. Fourteen-day CGM metrics predicted microvascular diabetes complications similarly to glycated hemoglobin. <b><i>Clinical Trials Registration:</i></b> Not a clinical trial.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Controlled Trial Using Continuous Glucose Monitoring to Guide Food Choices and Diabetes Self-Care in People with Type 2 Diabetes not Taking Insulin.","authors":"Thomas W Martens, Holly J Willis, Richard M Bergenstal, Davida F Kruger, Esra Karslioglu-French, Devin W Steenkamp","doi":"10.1089/dia.2024.0579","DOIUrl":"https://doi.org/10.1089/dia.2024.0579","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Continuous glucose monitoring (CGM) is an effective tool for individuals with type 2 diabetes (T2D) on insulin. This study evaluated the effect of using CGM to reduce hyperglycemia, by focusing on food and lifestyle choices, in people with T2D not taking insulin. <b><i>Methods:</i></b> A 6-month randomized, prospective four-center study was conducted. The primary end point was a within-group reduction in time above range >180 mg/dL (TAR180) at 3 months. Participants were asked not to make diabetes medication changes in the first 3 months. Seventy-two adults not on insulin or sulfonylurea therapy, with glycated hemoglobin (HbA1c) 7.5%-12%, were randomized to use CGM alone (<i>n</i> = 31) or CGM plus a food logging app (<i>n</i> = 41) to aid diabetes management. Participants attended guided education visits. Differences in CGM metrics, HbA1c, and body weight were compared. <b><i>Results:</i></b> The CGM alone group decreased TAR180 from 55% at baseline to 27% at 3 months (<i>P</i> < 0.001) and 21% at 6 months (<i>P</i> < 0.001); the CGM plus food logging app group decreased TAR180 from 53% at baseline to 30% at both 3 and 6 months (<i>P</i> < 0.001 for both). For all participants, time in range (70-180 mg/dL) increased from 46% at baseline to 71% at 3 months (<i>P</i> < 0.001) and to 72% at 6 months (<i>P</i> < 0.001). HbA1c and weight were reduced by 1.3% (<i>P</i> < 0.001) and 7 pounds (lbs.) (<i>P</i> < 0.001) for all participants at 6 months. <b><i>Conclusion:</i></b> People with T2D not taking insulin showed large, clinically significant improvements in CGM metrics and HbA1c when using either CGM alone or with a food logging app. This occurred with a near absence of medication changes in the first 3 months and were therefore likely due to changes in food and/or lifestyle choices.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts.","authors":"Jay M Sosenko, David Cuthbertson, Laura M Jacobsen, Maria J Redondo, Emily K Sims, Heba M Ismail, Kevan C Herold, Jay S Skyler, Brandon M Nathan","doi":"10.1089/dia.2024.0422","DOIUrl":"https://doi.org/10.1089/dia.2024.0422","url":null,"abstract":"<p><p><b><i>Objective:</i></b> We assessed whether there is an impactful glucose fraction independent of insulin secretion in autoantibody-positive individuals. <b><i>Research Design and Methods:</i></b> Baseline 2-h oral glucose tolerance test data from the TrialNet Pathway to Prevention (TNPTP; <i>n</i> = 6190) and Diabetes Prevention Trial-Type 1 (DPT-1; <i>n</i> = 705) studies were used. Linear regression of area under the curve (AUC) glucose versus Index60 was performed to identify two fractions: dependent (dAUCGLU) or independent (iAUCGLU) of insulin secretion. <b><i>Results:</i></b> The lack of correlation (<i>r</i> = 0.06) of iAUCGLU and the inverse correlation of dAUCGLU (<i>r</i> = -0.59) with the first-phase insulin response from DPT-1 were consistent with the independent and dependent designations of the glucose fractions. Correlations of AUC C-peptide were inverse with dAUCGLU and positive with iAUCGLU (TNPTP: <i>r</i> = -0.72, <i>r</i> = 0.57; DPT-1: <i>r</i> = -0.56, <i>r</i> = 0.60). The explained variance of AUC C-peptide increased markedly after separating AUC glucose into its fractions (from 4% to 85% in TNPTP; from 1% to 67% in DPT-1). The independent fraction contributed more to the increased glycemia of impaired glucose tolerance (IGT) than did the dependent fraction. Both dAUCGLU and iAUCGLU predicted IGT and type 1 diabetes (T1D) (<i>P</i> < 0.0001 for all). However, whereas dAUCGLU was more predictive of T1D (chi-square: 849 vs. 249), iAUCGLU was more predictive of IGT (chi-square: 451 vs. 176). <b><i>Conclusions:</i></b> A glucose fraction independent of insulin secretion was identified that was appreciable in autoantibody-positive individuals. It provides insight into the relation between glucose and C-peptide, contributes substantially to the glycemia of IGT, and predicts both T1D and IGT, particularly the latter.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}